WO2012078053A8 - Novel marker for detection of bladder cancer and/or inflammatory conditions of the bladder - Google Patents

Novel marker for detection of bladder cancer and/or inflammatory conditions of the bladder Download PDF

Info

Publication number
WO2012078053A8
WO2012078053A8 PCT/NZ2011/000238 NZ2011000238W WO2012078053A8 WO 2012078053 A8 WO2012078053 A8 WO 2012078053A8 NZ 2011000238 W NZ2011000238 W NZ 2011000238W WO 2012078053 A8 WO2012078053 A8 WO 2012078053A8
Authority
WO
WIPO (PCT)
Prior art keywords
bladder
detection
inflammatory conditions
novel marker
bladder cancer
Prior art date
Application number
PCT/NZ2011/000238
Other languages
French (fr)
Other versions
WO2012078053A1 (en
Inventor
Parry John Guilford
Mark Dalphin
Laimonis Kavalieris
Paul O'sullivan
Original Assignee
Pacific Edge Biotechnology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP11846559.0A priority Critical patent/EP2638398B1/en
Priority to SG2013036322A priority patent/SG190247A1/en
Priority to BR112013011875-0A priority patent/BR112013011875B1/en
Priority to AU2011339073A priority patent/AU2011339073A1/en
Priority to KR1020137015144A priority patent/KR101974135B1/en
Priority to NO11846559A priority patent/NO2638398T3/no
Priority to CA2817701A priority patent/CA2817701C/en
Priority to JP2013538681A priority patent/JP5985493B2/en
Application filed by Pacific Edge Biotechnology Limited filed Critical Pacific Edge Biotechnology Limited
Priority to US13/884,681 priority patent/US9982305B2/en
Priority to DK11846559.0T priority patent/DK2638398T3/en
Priority to ES11846559.0T priority patent/ES2667029T3/en
Priority to CN201180064437.6A priority patent/CN103314298B/en
Publication of WO2012078053A1 publication Critical patent/WO2012078053A1/en
Publication of WO2012078053A8 publication Critical patent/WO2012078053A8/en
Priority to HK14102696.7A priority patent/HK1189660A1/en
Priority to AU2017202630A priority patent/AU2017202630A1/en
Priority to US15/988,491 priority patent/US11208698B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Abstract

This invention relates to the use of human neutrophil marker interleukin 8 receptor B (IL8Rb) for detection of bladder cancer, and more particularly to the use of EL8Rb for discriminating between transitional cell carcinoma of the bladder (TCC) and inflammatory conditions of the bladder.
PCT/NZ2011/000238 2010-11-12 2011-11-11 Novel marker for detection of bladder cancer and/or inflammatory conditions of the bladder WO2012078053A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
US13/884,681 US9982305B2 (en) 2010-11-12 2011-11-11 Polymerase chain reaction test kits for detecting markers of bladder cancer
SG2013036322A SG190247A1 (en) 2010-11-12 2011-11-11 Novel marker for detection of bladder cancer and/or inflammatory conditions of the bladder
DK11846559.0T DK2638398T3 (en) 2010-11-12 2011-11-11 Hitherto UNKNOWN MARKET FOR THE DETECTION OF BLADE CANCER AND / OR INFLAMMATORY CONDITIONS IN THE BLADE.
KR1020137015144A KR101974135B1 (en) 2010-11-12 2011-11-11 Novel Marker for detection of bladder cancer and/or inflammatory conditions of the bladder
NO11846559A NO2638398T3 (en) 2010-11-12 2011-11-11
CA2817701A CA2817701C (en) 2010-11-12 2011-11-11 Novel marker for detection of bladder cancer and/or inflammatory conditions of the bladder
JP2013538681A JP5985493B2 (en) 2010-11-12 2011-11-11 Novel marker for detecting bladder cancer and / or inflammatory conditions of the bladder
EP11846559.0A EP2638398B1 (en) 2010-11-12 2011-11-11 Novel marker for detection of bladder cancer and/or inflammatory conditions of the bladder
BR112013011875-0A BR112013011875B1 (en) 2010-11-12 2011-11-11 BLADDER CANCER SCREENING METHOD, DEVICE AND KIT FOR DETECTION OF BLADDER CANCER
AU2011339073A AU2011339073A1 (en) 2010-11-12 2011-11-11 Novel marker for detection of bladder cancer and/or inflammatory conditions of the bladder
ES11846559.0T ES2667029T3 (en) 2010-11-12 2011-11-11 Novel marker for the detection of bladder cancer and / or inflammatory conditions of the bladder
CN201180064437.6A CN103314298B (en) 2010-11-12 2011-11-11 For detection of the novel mark of the inflammatory disease of carcinoma of urinary bladder and/or bladder
HK14102696.7A HK1189660A1 (en) 2010-11-12 2014-03-18 Novel marker for detection of bladder cancer and or inflammatory conditions of the bladder
AU2017202630A AU2017202630A1 (en) 2010-11-12 2017-04-20 Novel marker for detection of bladder cancer and/or inflammatory conditions of the bladder.
US15/988,491 US11208698B2 (en) 2010-11-12 2018-05-24 Methods for detection of markers bladder cancer and inflammatory conditions of the bladder and treatment thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ589251 2010-11-12
NZ589251A NZ589251A (en) 2010-11-12 2010-11-12 Novel marker for detection of bladder cancer

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/884,681 A-371-Of-International US9982305B2 (en) 2010-11-12 2011-11-11 Polymerase chain reaction test kits for detecting markers of bladder cancer
US15/988,491 Division US11208698B2 (en) 2010-11-12 2018-05-24 Methods for detection of markers bladder cancer and inflammatory conditions of the bladder and treatment thereof

Publications (2)

Publication Number Publication Date
WO2012078053A1 WO2012078053A1 (en) 2012-06-14
WO2012078053A8 true WO2012078053A8 (en) 2013-05-30

Family

ID=46207373

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NZ2011/000238 WO2012078053A1 (en) 2010-11-12 2011-11-11 Novel marker for detection of bladder cancer and/or inflammatory conditions of the bladder

Country Status (17)

Country Link
US (2) US9982305B2 (en)
EP (1) EP2638398B1 (en)
JP (1) JP5985493B2 (en)
KR (1) KR101974135B1 (en)
CN (1) CN103314298B (en)
AU (2) AU2011339073A1 (en)
BR (1) BR112013011875B1 (en)
CA (1) CA2817701C (en)
DK (1) DK2638398T3 (en)
ES (1) ES2667029T3 (en)
HK (1) HK1189660A1 (en)
NO (1) NO2638398T3 (en)
NZ (1) NZ589251A (en)
PT (1) PT2638398T (en)
SG (2) SG10201509322YA (en)
TW (1) TWI618797B (en)
WO (1) WO2012078053A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015073870A1 (en) * 2013-11-15 2015-05-21 North Carolina State University Chromosomal assessment to diagnose urogenital malignancy in dogs
NZ720626A (en) * 2013-11-21 2021-12-24 Pacific Edge Ltd Triaging of patients having asymptomatic hematuria using genotypic and phenotypic biomarkers
US10501806B2 (en) 2014-04-15 2019-12-10 North Carolina State University Chromosomal assessment to differentiate histiocytic malignancy from lymphoma in dogs
WO2016014941A1 (en) 2014-07-24 2016-01-28 North Carolina State University Method to diagnose malignant melanoma in the domestic dog
FR3044613B1 (en) * 2015-12-08 2018-11-30 Faurecia Interieur Industrie INTERIOR VEHICLE EQUIPMENT EQUIPPED WITH A SCREEN, CORRESPONDING MANAGEMENT METHOD
EP3464640B1 (en) 2016-05-31 2021-06-30 North Carolina State University Methods of mast cell tumor prognosis and uses thereof
CN106520949B (en) * 2016-11-14 2019-05-14 北京开景基因技术有限公司 Biomarker is used to prepare the purposes of cystitis glandularis diagnostic reagent
CN106709267A (en) * 2017-01-25 2017-05-24 武汉贝纳科技服务有限公司 Data acquisition method and device
EP3450981A1 (en) * 2017-08-28 2019-03-06 Trizell GmbH Btnl8 as a marker for tregs
CN108866194B (en) * 2018-08-16 2021-03-26 杭州可帮基因科技有限公司 Gene group for detecting bladder cancer and application thereof
CN109055559A (en) * 2018-09-28 2018-12-21 爱尔生基因医学科技有限公司 A kind of specific primer detecting bladder cancer and kit and its detection method
CN116024345B (en) * 2023-01-12 2023-12-01 上海仁度生物科技股份有限公司 Real-time fluorescent nucleic acid isothermal amplification detection kit for bladder cancer and special primer and probe thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US20070031841A1 (en) * 2001-02-28 2007-02-08 Choong-Chin Liew Method for the detection of gene transcripts in blood and uses thereof
WO2000052204A2 (en) * 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
KR100768985B1 (en) * 1999-09-10 2007-10-22 무라마쯔 다카시 Early cancer tumor marker
US6355170B1 (en) 2000-02-16 2002-03-12 Barry H. Hall Dual manifold filtering system
AU2001292802A1 (en) * 2000-09-19 2002-04-02 Dana-Farber Cancer Institute Inc. Genetic markers for tumors
US6515001B2 (en) * 2001-03-05 2003-02-04 Chemokine Therapeutic Corporation IL-8 receptor ligands-drugs for inflammatory and autoimmune diseases
US20040076955A1 (en) * 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
WO2005103702A2 (en) 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 2 (cxcr2)
US7256707B2 (en) 2004-06-18 2007-08-14 Los Alamos National Security, Llc RF transmission line and drill/pipe string switching technology for down-hole telemetry
TWI661199B (en) * 2004-07-23 2019-06-01 太平洋愛吉生技股份有限公司 Urine markers for detection of bladder cancer
WO2007026895A1 (en) * 2005-09-02 2007-03-08 Toray Industries, Inc. Kit and method for detection of urothelial cancer
US20090269744A1 (en) 2005-10-28 2009-10-29 Exonhit Therapeutics Sa Cancer detection method
CN100366637C (en) * 2005-11-17 2008-02-06 中国人民解放军第四军医大学 Human interleukin 8 antagonist protein and preparation method thereof
NZ545243A (en) * 2006-02-10 2009-07-31 Pacific Edge Biotechnology Ltd Urine gene expression ratios for detection of cancer
CN101101290A (en) * 2006-11-30 2008-01-09 山东省医药生物技术研究中心 Tumour serum mark and its uses
EP2136911A2 (en) * 2007-01-19 2009-12-30 Biodot, Inc. Systems and methods for high speed array printing and hybridization
CN101768214B (en) * 2008-10-06 2013-03-13 复旦大学 Human tumor marker-Tim17 polypeptide and application thereof
EP2366162A1 (en) 2008-11-18 2011-09-21 Collabrx, Inc. Individualized cancer treatment
US20100166739A1 (en) * 2008-12-30 2010-07-01 Lipella Paharmaceuticals Inc. Methods and Compositions for Diagnosing Urological Disorders
NZ720626A (en) * 2013-11-21 2021-12-24 Pacific Edge Ltd Triaging of patients having asymptomatic hematuria using genotypic and phenotypic biomarkers

Also Published As

Publication number Publication date
JP5985493B2 (en) 2016-09-06
NZ589251A (en) 2014-07-25
WO2012078053A1 (en) 2012-06-14
JP2013543974A (en) 2013-12-09
US20170002420A1 (en) 2017-01-05
HK1189660A1 (en) 2014-06-13
SG10201509322YA (en) 2015-12-30
EP2638398A4 (en) 2014-03-26
AU2011339073A1 (en) 2013-06-20
CA2817701A1 (en) 2012-06-14
KR20140040070A (en) 2014-04-02
US20180298452A1 (en) 2018-10-18
NO2638398T3 (en) 2018-06-23
SG190247A1 (en) 2013-07-31
AU2017202630A1 (en) 2017-05-18
EP2638398A1 (en) 2013-09-18
TWI618797B (en) 2018-03-21
KR101974135B1 (en) 2019-04-30
ES2667029T3 (en) 2018-05-09
PT2638398T (en) 2018-06-01
CN103314298B (en) 2016-05-25
US9982305B2 (en) 2018-05-29
US11208698B2 (en) 2021-12-28
EP2638398B1 (en) 2018-01-24
BR112013011875A2 (en) 2021-04-13
CN103314298A (en) 2013-09-18
BR112013011875B1 (en) 2022-06-14
TW201305350A (en) 2013-02-01
CA2817701C (en) 2021-10-19
DK2638398T3 (en) 2018-05-07

Similar Documents

Publication Publication Date Title
WO2012078053A8 (en) Novel marker for detection of bladder cancer and/or inflammatory conditions of the bladder
WO2012083969A3 (en) Microrna for diagnosis of pancreatic cancer
WO2012068383A3 (en) ncRNA AND USES THEREOF
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
WO2010077740A3 (en) Novel antiviral compounds, compositions, and methods of use
WO2010078945A3 (en) Cancer treatment
WO2011038155A3 (en) Genetic analysis
WO2009108860A8 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
WO2012174256A3 (en) Dna methylation profiles in cancer
CA2835730C (en) Molecular markers in prostate cancer
WO2008089397A3 (en) Adrb2 cancer markers
WO2009030884A3 (en) Mannosylated butyrophilin tumour markers
WO2013036543A3 (en) Molecular imaging of cancer cells in vivo
EP2611941A4 (en) Gene signatures for cancer diagnosis and prognosis
WO2012012714A3 (en) Methods of detecting neurological or neuropsychiatric diseases or conditions
IT1403129B1 (en) PROCEDURE FOR THE PRODUCTION OF HIGH MANGANESE STEEL WITH MECHANICAL RESISTANCE AND HIGH FORMABILITY, AND STEEL SO OBTAINABLE.
WO2012135340A3 (en) Compositions and methods for diagnosing cancer
AP2011005978A0 (en) 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation.
WO2011106709A3 (en) Epithelial biomarkers for cancer prognosis
WO2011097509A3 (en) Hypoxia-related gene signatures for cancer classification
WO2014036040A3 (en) Methods for diagnosis, prognosis and methods of treatment
SG10201407036YA (en) Markers of Endothelial Progenitor Cells and Uses Thereof
WO2007106425A3 (en) Biomarkers of the dysplastic state of cells
WO2011079277A3 (en) Genetic markers associated with drought tolerance in maize
WO2010079117A3 (en) Transplastomic plants free of the selectable marker

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11846559

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2013538681

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2817701

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011846559

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20137015144

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2011339073

Country of ref document: AU

Date of ref document: 20111111

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013011875

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 13884681

Country of ref document: US

ENP Entry into the national phase

Ref document number: 112013011875

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130513